This HITLAB summary of evidence presents an independent analysis of the scientific, clinical, regulatory, and commercial evidence demonstrating the urgent global need for representative genomic biorepositories. The findings confirm that existing genomic databases—across public, private, academic, and national systems—remain structurally unrepresentative of the world’s population. This deficiency is documented across fifteen years of peer-reviewed literature, federal regulatory mandates, and biopharma capital deployment patterns.

The purpose of this document is to identify, organize, and evaluate the evidence describing systemic deficiencies in the world’s genomic infrastructure—specifically the biobanks, biorepositories, and data ecosystems that underpin precision medicine, AI-enabled drug discovery, and national BioDefense. The analysis examines whether any existing platform or institution has addressed these deficiencies at the scale required by current scientific, regulatory, and commercial demands.

Based on the evidence reviewed, this paper also profiles a solution provider—IndyGeneUS Bio— whose architecture, institutional agreements, and validated sample base directly address the structural gaps identified in the global genomic reference infrastructure. Its inclusion is not an assertion of preference, but the result of an evidence-driven assessment of what is operationally available today.